We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





South Korea's Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval

By HospiMedica International staff writers
Posted on 10 Sep 2020
Print article
Image: South Korea`s Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval (Photo courtesy of Celltrion Group)
Image: South Korea`s Celltrion to Begin Mass Production of Experimental COVID-19 Antibody Drug Ahead of EUA Approval (Photo courtesy of Celltrion Group)
Celltrion Group (Incheon, South Korea) plans to soon begin commercial production of its experimental COVID-19 antiviral antibody treatment even as the company continues to conduct clinical trials of the antibody drug.

Celltrion had completed identification of antibody candidates for an antiviral treatment in April and announced positive pre-clinical results for its COVID-19 antiviral antibody treatment in June, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2. The treatment became the first COVID-19 antibody drug to be tested on humans in South Korea after receiving regulatory approval in July for clinical trials, stated a report by Reuters.

Celltrion has now reportedly completed Phase 1 trial involving 32 volunteers in South Korea and is enrolling an additional nine participants for another Phase 1 study ahead of later stage trials, for which regulatory reviews are underway. The company is conducting separate overseas human trials of its treatment in the UK, which will be followed by global second and third stage trials in COVID-19 patients with mild and moderate symptoms, according to the Reuters report.

“We have confirmed the safety of the antiviral antibody drug in the process of the local Phase 1 clinical trial,” Kwon Ki-sung, head of Celltrion’s R&D unit, told Reuters.

Related Links:
Celltrion Group

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Heart-Lung Machine
HL 40

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.